Business
Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress
Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T. CAMBRIDGE, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc.
About this update from Relay Therapeutics, Inc.
[{"type":"text","content":"Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T.\nCAMBRIDGE, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that a late breaking abstract of interim clinical data from the ReFocus trial for RLY-4008 has been selected for an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress, being held September 9-13, 2022. The presentation will focus on dose escalation and dose expansion patients with FGFR2 fusion, FGFR inhibitor-naïve cholangiocarcinoma. Relay Therapeutics will host a conference call on September 12, 2022 at 8:00 am E.T. to discuss the results of the presentation. Late Breaking Oral Presentation Details for RLY-4008:Title: Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with a FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trialAbstract Number: LBA12Session Title: Proffered Paper Session 2: GI, Upper DigestiveDate/Time: September 11, 2022 at 3:45 pm C.E.S.T./9:45 am E.T. The ESMO website indicates that late breaking abstracts will be published on the September 7, 2022 at 7:05 pm E.T. Conference Call Information Relay Therapeutics will host a conference call and live webcast on September 12, 2022 at 8:00 am E.T. Registration and dial-in for the conference call may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available following the event. The presentation from the ESMO Congress will also be available on the Relay Therapeutics website under Publications: https://relaytx.com/publications/. About RLY-4008 RLY-4008 is a potent, selective and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. FGFR2 is one of four members of the FGFR family, a set of closely related proteins with highly similar protein sequences and properties. Preclinically, RLY-4008 demonstrated FGFR2-dependent killing in cancer cell lines and induced regression in in vivo models, while mi...